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deficits may be due to an intact blood–brain barrier
(BBB), which restricts entry of serum IgG into the
CNS. It has recently been reported that AQP4-IgG
can be present in serum several years before clinical
onset of NMO.7 In addition, experimental studies
have shown induction of NMO-like histopathology
by transfer of human AQP4-IgG to animals only
provided BBB breakdown.2
Further studies are needed to evaluate the neuro-
logic outcome of infants and children of mothers with
NMO given the evidence that AQP4-IgG can be pas-
sively transferred to the fetus.
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NULL MUTATION IN SCN9A IN WHICH NOXIOUS
STIMULI CAN BE DETECTED IN THE ABSENCE OF
PAIN
The term nociception was originally defined by Sher-
rington1 as the neural process by which high-threshold
stimuli (which cause tissue injury) are detected. This is
distinct from pain, which is defined by the quality of the
sensory percept (i.e., unpleasant), is not always evoked
by a noxious stimulus, and can also be experienced in
the absence of a noxious stimulus. In man, recessive
loss of function mutations in the SCN9A gene, encod-
ing the a subunit of Nav1.7, results in anosmia and the
congenital inability to experience pain,2–4 but there have
been few reports of detailed sensory testing in these
patients.
Case report. A 27-year-old man who participated in
the Painful Channelopathies Study (NRES-UK
reference: 12/LO/0017) had a history of self-
mutilating behavior during childhood and multiple
painless injuries with normal cognitive development.
He had never perceived pain but reported that
otherwise somatosensation was normal. In his late
teens, he learned to avoid injury by attending to
what he described as a tingling sensation, which was
not unpleasant but that he noted only occurred in
the context of threatened tissue injury. The family
pedigree is shown in the figure, A. He had 2 sisters,
one of whom died in childhood as a consequence of
sepsis. The surviving sister also has congenital inability
to experience pain.
The proband presented with short stature of
149 cm. He was anosmic. Tone and power were nor-
mal throughout and all deep tendon reflexes were pre-
served. He had no impairment in light touch,
vibration detection, or proprioception. Pinprick was
not perceived as painful although he could detect that
it was pointed and a flare developed shortly after
stimulation.
Genetic testing for SCN9Amutations in the index
case and his sister (figure, A) revealed compound het-
erozygous mutations (figure, B). Nerve conduction
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Figure Detailed sensory phenotyping in a patient with compound heterozygous null mutations in Nav1.7
(A) The family pedigree shows the proband (arrow) and 2 sisters with congenital inability to experience pain. (B) Cartoon
shows the structure of Nav1.7 showing the typical 4-domain structure of voltage-gated sodium channels each with 6
transmembrane segments. The mutations are as follows: a premature stop codon at arginine 830 (within domain 2) and
a frameshift at glutamate 1773 within the C-terminal domain. (C) Graphical representation of sensory testing in the pro-
band expressed as Z scores: cold detection threshold (CDT), warm detection threshold (WDT), thermal sensory limen (TSL),
cold pain threshold (CPT), heat pain threshold (HPT), pressure pain threshold (PPT), mechanical pain threshold (MPT),
mechanical pain sensitivity (MPS), wind-up ratio (WUR), mechanical detection threshold (MDT), and vibration detection
threshold (VDT). (D) Graph represents the patient’s rating of his tingling sensation on a numerical rating scale (means 6
SE) in response to suprathreshold thermal stimuli delivered in a randomized manner. The threshold for this distinct sensa-
tion is clearly in the noxious range and the intensity of the sensation encodes the strength of the thermal stimulus. (E)
Photomicrograph of skin section immunostained for PGP 9.5 (red) to demonstrate nerve fibers and collagen type IV (green)
to show the basement membrane. Fibers are clearly seen in the dermal plexus and some are crossing into the epidermis
(arrows); however, the intraepidermal nerve fiber densityis reduced to 3.98 fibers/mm. Scale bar: 50 mm.
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studies demonstrated small-amplitude sural sensory
nerve action potentials (table e-1 on the Neurology®
Web site at Neurology.org). Quantitative sensory
testing was performed according to the German Neu-
ropathic Pain Network5 (e-Methods). He did not
experience pain (i.e., there was no unpleasant sensa-
tion) in response to any stimulus applied including
extremes of temperature or mechanical stimuli. His
mechanical detection and vibration detection thresh-
olds were normal. He was hyposensitive to warm and
cool stimuli (figure, C). High temperatures and strong
mechanical stimuli evoked a mild tingling sensation.
This sensation was never unpleasant but he had learned
to use it as an injury signal. We therefore performed
suprathreshold thermal stimulation by giving random-
ized thermal stimuli and asking him to rate the inten-
sity of this sensation (figure, D). The threshold for this
stimulus was in the noxious range at 42°C and the
intensity of the sensation could encode the strength
of the stimulus. Skin biopsy taken from the distal leg
showed that intraepidermal nerve fibers were present
although at a density below the lower limit of normal
(figure, E).
Discussion. The index case reported in this kindred
demonstrated insensitivity to pain, normal large-fiber
sensory function, and anosmia: typical features of
congenital insensitivity to pain (CIP) secondary to
SCN9A mutations. Genetic testing revealed compound
heterozygous mutations in SCN9A: a premature stop
codon in coding exon 15 (c.2488C.T), which has
previously been reported,3 and a previously unreported
1-bp deletion within coding exon 26 (c.5318delA),
which induces a frameshift at position 1773 in the
C-terminal domain of the channel.
The patient had identified a sensation that was not
unpleasant but only occurred in the context of strong
mechanical or thermal stimuli that could cause tissue
injury. The sensation was mild, localized to the stim-
ulus, and had a tingling quality to it. He used this sen-
sation as a warning signal and had managed to reduce
the frequency of injury. It is currently unclear as to
the mechanism by which he can detect tissue injury
in the absence of pain. Nociceptors still innervate
the skin, albeit at a lower density than in age-
matched controls. The proposed mechanisms through
which null mutations in Nav1.7 result in inability to
experience pain include impaired transduction in
nociceptor terminals, action potential transmission
along the axon, and release of neurotransmitter from
central terminals of sensory afferents.6,7 It is possible
that a small population of nociceptive afferents are
able to function in the absence of Nav1.7 but provide
insufficient input to drive pain sensation. This case
further emphasizes that the detection of noxious stim-
uli and the sensation of pain are distinct and could also
have practical implications if other patients with CIP
can train themselves to attend to sensations that may
indicate potential tissue injury but are not painful.
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